Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHARMATOP
NCT04986631Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topiramate in childhood obesity, sponsored by University of Minnesota. Primary endpoint: Percent Body Mass Index Change at 14 weeks. Started Apr 2022; status: completed.
02
Drugs
topiramate
03
Conditions
childhood obesity
Beyond the preview
Go deeper on NCT04986631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986631.